Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 17, 2018 - Issue 3
Submit an article Journal homepage
326
Views
21
CrossRef citations to date
0
Altmetric
Drug Safety Evaluation

The launch of opicapone for Parkinson’s disease: negatives versus positives

Ana Castro CaldasNeurology Service, Department of Neurosciences, Hospital de Santa Maria, Lisbon, Portugal;Neurology Department, Instituto de Medicina Molecular, Lisbon, Portugal;Neurology Department, CNS - Campus Neurológico Sénior, Torres Vedras, PortugalCorrespondence[email protected]
View further author information
,
Tiago TeodoroNeurology Department, Instituto de Medicina Molecular, Lisbon, Portugal;Neurology Department, St George’s, University of London & St George’s University Hospitals NHS Foundation Trust, London, United KingdomView further author information
&
Joaquim J FerreiraNeurology Department, Instituto de Medicina Molecular, Lisbon, Portugal;Neurology Department, CNS - Campus Neurológico Sénior, Torres Vedras, Portugal;Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Lisbon, PortugalORCID Iconhttp://orcid.org/0000-0003-3950-5113View further author information
ORCID Icon
Pages 331-337 | Received 26 Oct 2017, Accepted 24 Jan 2018, Published online: 07 Feb 2018

References

  • Bonifácio MJ, Palma PN, Almeida L, et al. Catechol-O-methyltransferase and its inhibitors in Parkinson’s disease. CNS Drug Rev. 2007;13(3):352–379.
  • Bonifati V, Meco G. New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson’s disease. Pharmacol Ther. 1999;81(1):1–36.
  • Deane KH, Spieker S, Clarke CE. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson’s disease. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD004554.
  • Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur J Neurol. 2013;20(1):5–15.
  • Lang A, Lees A. Management of Parkinson’s disease: an evidence-based review. Mov Disord. 2002;17 Suppl 4:S1–166.
  • Brooks DJ. Safety and tolerability of COMT inhibitors. Neurology. 2004;62(1 Suppl 1):S39–46.
  • Bet L, Bareggi SR, Pacei F, et al. Bimodal administration of entacapone in Parkinson’s disease patients improves motor control. Eur J Neurol. 2008 Mar;15(3):268–273.
  • Kiss LE, Ferreira HS, Torrão L, et al. Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. J Med Chem. 2010 Apr 22;53(8):3396–3411.
  • Ferreira JJ, Lees A, Rocha J-F, et al. Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016 Feb;15(2):154–165. [ Epub 2015 Dec 23].
  • Lees AJ, Ferreira J, Rascol O, et al. Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations. JAMA Neurol. 2017;74(2):197.
  • Bonifácio MJ, Torrão L, Loureiro AI, et al. Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat. Br J Pharmacol. 2015 Apr;172(7):1739–1752. [ Epub 2015 Jan 20].
  • Bonifácio MJ, Sutcliffe JS, Torrão L, et al. Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor. Neuropharmacology. 2014;77:334–341.
  • Pinto R, Vaz-da-Silva M, Lopes N, et al. Cardiac safety of opicapone in patients with Parkinson’s disease: analysis of the centralized phase III ECG dataset [abstract]. Move Disord. 2015;30 Suppl 1:294.
  • Rocha JF, Santos A, Falcão A, et al. Effect of moderate liver impairment on the pharmacokinetics of opicapone. Eur J Clin Pharmacol. 2014 Mar;70(3):279–286. [ Epub 2013 Nov 24].
  • Pinto R, l’Hostis P, Patat A, et al. Evaluation of opicapone on cardiac repolarization in a thorough QT/QTc study. Clin Pharmacol Drug Dev. 2015 Nov;4(6):454–462. [ Epub 2015 May 7].
  • Ferreira JJ, Rocha JF, Falcão A, et al. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson’s disease. Eur J Neurol. 2015 May;22(5):815–25, e56. [ Epub 2015 Feb 4].
  • Rocha J-F, Ferreira JJ, Falcão A, et al. Effect of 3 single-dose regimens of opicapone on levodopa pharmacokinetics, catechol-o-methyltransferase activity and motor response in patients with Parkinson disease. Clin Pharmacol Drug Dev. 2016 May;5(3):232–240. [ Epub 2015 Oct 20].
  • Lopes N, Ferreira JJ, Lees A, et al. Hepatic safety of opicapone in Parkinson’s disease patients [abstract]. Move Disord. 2015;30 Suppl 1:263.
  • Lees A, Ferreira JJ, Lopes N, et al. Efficacy and safety of opicapone in patients over 70 years with Parkinson’s disease and motor fluctuations [abstract]. Move Disord. 2015;30 Suppl 1:258.
  • Lopes N, Ferreira JJ, Lees A, et al. Exploratory efficacy of opicapone in combination with dopamine agonists or MAO-B inhibitors on the treatment of motor fluctuations in Parkinson’s disease [abstract]. Move Disord. 2015;30 Suppl 1:264.
  • Costa R, Oliveira C, Pinto R, et al. One-year open-label efficacy and safety of opicapone in Parkinson’s disease BIPARK-II study [abstract]. Move Disord. 2014;29 Suppl 1:630.
  • Cumulative and interval summary tabulation of serious and non-serious adverse reactions of opicapone from post-marketing data sources [ Unpublished raw data]. 2018.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.